Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization

Table 1 Baseline characteristic for the cohort, n = 792

Characteristics	Values
Age at start, yr, mean ± SD	56.4 ± 11.6
Gender, men/women, n (%)	663 (83.7)/129 (16.3)
Etiology, HBV/non-HBV, n (%)	681 (86.0)/111 (14.0)
Child-Pugh class, A/B, n (%)	742 (93.7)/50 (6.3)
ALBI grade, 1/2/3, n (%)	323 (40.8)/458 (57.8)/11 (1.4)
Tumor size, cm, mean ± SD/median (IQR)	8.6 ± 4.1/8.2 (5.2-11.5)
Tumor number, mean ± SD/median (IQR)	2.4 ± 2.2/1 (1-3)
AFP, ≤ 400/> 400 ng/mL/NA, n (%)	431 (54.4)/337 (42.6)/24 (3.0)
White blood cell, 109/L, mean ± SD	5.8 ± 2.6
Red blood cell, 106/L, mean ± SD	4.4 ± 0.7
Platelets, 109/L, mean ± SD	158.4 ± 88.9
International normalized ratio, mean ± SD	1.08 ± 0.12
Alanine aminotransferase, U/L, mean ± SD	53.0 ± 47.3
Aspartate aminotransferase, U/L, mean ± SD	67.5 ± 59.6
Albumin, g/L, mean ± SD	38.7 ± 7.0
Total bilirubin, μmol/L, mean ± SD	18.1 ± 8.5
Urea nitrogen, mmol/L, mean ± SD	5.5 ± 3.1
Serum creatinine, μmol/L, mean ± SD	71.9 ± 20.7
Sessions of TACE, mean ± SD/ median (IQR)	2.9 ± 2.0/2 (1-4)

SD: Standard deviation; IQR: Interquartile range; HBV: Hepatitis B virus; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization.